KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Debt (2016 - 2026)

NovoCure's Total Debt history spans 12 years, with the latest figure at $195.5 million for Q1 2026.

  • On a quarterly basis, Total Debt rose 100.58% to $195.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $195.5 million, a 100.58% increase, with the full-year FY2025 number at $195.0 million, up 100.46% from a year prior.
  • Total Debt hit $195.5 million in Q1 2026 for NovoCure, roughly flat from $195.0 million in the prior quarter.
  • Over the last five years, Total Debt for NVCR hit a ceiling of $569.7 million in Q1 2024 and a floor of $97.0 million in Q2 2024.
  • Historically, Total Debt has averaged $350.0 million across 5 years, with a median of $379.2 million in 2022.
  • Biggest five-year swings in Total Debt: crashed 82.9% in 2024 and later soared 100.58% in 2026.
  • Tracing NVCR's Total Debt over 5 years: stood at $565.5 million in 2022, then increased by 0.44% to $568.0 million in 2023, then crashed by 82.87% to $97.3 million in 2024, then surged by 100.46% to $195.0 million in 2025, then increased by 0.21% to $195.5 million in 2026.
  • Business Quant data shows Total Debt for NVCR at $195.5 million in Q1 2026, $195.0 million in Q4 2025, and $194.6 million in Q3 2025.